

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/22946

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A01N 43/40, 43/42; A61K 31/47, 31/445; C07J 31/00, 41/00, 9/00

US CL : 514/314, 317, 822; 552/550

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
U.S. : 514/314, 317, 822; 552/550

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
EAST (USPATS, USGPUB, USOCR), CAPLUS, BIOSIS, MEDLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SMYTHE, M.A., et al. Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia. American Journal of Hematology, 2002, Vol. 71, pages 50-52, especially p.52.	1-13
X	KONDO, L.M., et al. Argatroban for prevention and treatment of thromboembolism in heparin-induced thrombocytopenia. Annals of Pharmacotherapy, April 2001, Vol 35, pages 440-451, especially pages 442 and 446.	1, 3-13
X	ADKINS, J.C., et al. Lepirudin: a review of its potential place in the management of thrombotic disorders. BioDrugs. September 1998, Vol. 10, No.3, pages 227-255, especially p. 228, 232-233, 239-241, 247, and 249-251.	1-5, 7-9
X	LAPOSATA, M.L., et al. College of American Pathologists conference XXXI on laboratory monitoring of anticoagulant therapy: The clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Archives of Pathology and Laboratory Medicine. September 1998, Vol. 122, No. 9, pages 799-807, especially pages 801 and 804-805.	1-9
Y		10-13



Further documents are listed in the continuation of Box C.



See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

18 January 2005 (18.01.2005)

Date of mailing of the international search report

15 MAR 2005

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Facsimile No. (703) 305-3230

Authorized officer

Lora E Barnhart

Telephone No. 571-272-1600

**INTERNATIONAL SEARCH REPORT**International application No.  
PCT/US04/22946**C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HURSTING, M.J. et al. The international normalized ratio during concurrent warfarin and argatroban anticoagulation: differential contributions of each agent and effects of the choice of thromboplastin used. Clinical Chemistry. 1999, Vol. 45, No. 3, pages 409-412, especially p. 411.	1-13